NCT04163198

Brief Summary

Patients with neuromuscular diseases (NMD) can suffer from a range of respiratory problems due to respiratory muscle weakness. Cough muscle weakness means secretion clearance from the airways can be problematic, a source of infection, and importantly a cause of death, in this patient group. Therefore, these patients are often supported with devices to aid clearance, such as mechanical insufflation-exsufflation (MIE). Although evidence supports the use of these devices, the optimal technique or settings on the device are not clear. Increasingly, higher pressures are used during MIE and recent work has demonstrated that there may be a physiological benefit to this. However, higher pressures increase the risk of causing lung collapse and may cause detriment to blood flow back to the heart, which is important as NMD patients frequently have concurrent heart muscle weakness. Further, recent work has demonstrated that higher pressures can cause closure of the throat, which is counter-productive in secretion clearance. The overall aim of this study is to investigate methods to manipulate MIE to improve secretion clearance in patients with NMD. The questions it seeks to answer are: (i) how can we maximally improve lung recruitment during inspiration, whilst maintaining patient comfort and lower pressures (ii) what is the smallest pressure difference required in expiration to achieve an improvement in cough (iii) do these proposed changes to MIE also cause throat closure (iv) what factors do patients believe contribute to their adherence to MIE therapy? Patients with slowly progressive or stable neuromuscular diseases will be included in the study. Participation will involve two visits to the Lane Fox Respiratory Unit, each lasting approximately four hours. Patients will be recruited from specialist neuromuscular respiratory clinics by their clinical teams.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 12, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 14, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

December 19, 2019

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2025

Completed
Last Updated

April 3, 2024

Status Verified

March 1, 2024

Enrollment Period

5.3 years

First QC Date

November 12, 2019

Last Update Submit

April 2, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cough peak expiratory flow (cPEF)

    Change in cPEF with different modalities of MI-E

    2 days

Study Arms (2)

Insufflation optimisation

EXPERIMENTAL

Patient will receive different inspiratory time and expiratory time, and inspiratory flow at a fixed insufflation pressure. To determine how best to recruit lung.

Device: Insufflation

Exsufflation optimisation

EXPERIMENTAL

Patient will receive different expiratory pressures at a fixed inspiratory pressure (optimal determine in Arm 1). To determine minimum flow bias needed to generate cPEF

Device: Exsufflation

Interventions

Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.

Insufflation optimisation

Patients will receive different exsufflation pressures at fixed insufflation pressure.

Exsufflation optimisation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Stable or slowly progressive neuromuscular disease
  • Respiratory muscle weakness (FVC \<60%, snip \<60%, sleep disordered breathing)
  • Clinical evidence of respiratory secretions or cough peak expiratory flow \<270 and history of lower respiratory tract infection
  • Documented clinical stability by supervising clinician

You may not qualify if:

  • Rapidly progressive neuromuscular disease (such as motor neuron disease)
  • Decompensated respiratory failure (pH \< 7.35)
  • Pregnancy
  • Aged \<18
  • Change in ventilator settings in preceding 4 weeks
  • Significant physical or psychiatric co-morbidity that would prevent compliance with trial protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guys & St. Thomas' NHS Foundation Trust

London, SE1 7EH, United Kingdom

RECRUITING

MeSH Terms

Conditions

Neuromuscular Diseases

Interventions

Insufflation

Condition Hierarchy (Ancestors)

Nervous System Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and ProceduresDiagnosisTherapeutics

Study Officials

  • Patrick Murphy, PhD

    Guy's and St Thomas' NHS Foundation Trust

    STUDY CHAIR

Central Study Contacts

Patrick Murphy, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 12, 2019

First Posted

November 14, 2019

Study Start

December 19, 2019

Primary Completion

March 31, 2025

Study Completion

May 31, 2025

Last Updated

April 3, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations